Ronan Kelly, Director of Precision Medicine and Scientific Discovery at Baylor University Medical Center, shared a post on LinkedIn:
“As we gather this weekend at ASCO 2026 in Chicago, the Texas Cancer Interception Institute (TCII) team will be engaging with existing and new industry collaborators advancing next-generation frameworks for population-scale early cancer detection.
Our work integrates health system wide multiomics profiling, radiomic feature extraction, digital pathology, and AI-enabled population analytics to improve signal detection across pre-symptomatic individuals in an attempt to improve cancer outcomes.
The objective is to shift the practice of oncology from episodic diagnosis when a patient presents when they are sick with alarm symptoms towards continuous, data-driven interception that empowers patients to test when and where they want using new technologies in an attempt to improve outcomes and increase long term survivorship.
Within Texas, we are building the infrastructure to operationalize these methods at scale, supported by our forthcoming industry first formal Cancer Interception Command Center housed at Baylor University Medical Center in Dallas.”
Other articles featuring Ronan Kelly on OncoDaily.